With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice.

The book first reviews fundamental issues including epidemiology, screening, risk reduction, diagnosis and pathologic characterization, staging, and imaging. This includes strategies for improving the accuracy of PSA screening and an update on controversies surrounding the ISUP Modified Gleason Score. The book covers novel molecular and genotype profiling in prostate cancer, including morphometric and systems pathology. Detailed information is provided on radiographic imaging for diagnosis and staging. The treatment sections of the book correspond to the staging of disease. The treatment of localized disease addresses the range of multidisciplinary management options including a discussion of prostate cancer's impact on the quality of life. A detailed review of multimodal therapies (medical, surgical, and radiologic) addresses the treatment of localized advanced disease, and coverage of advanced metastatic prostate cancer reviews current management options including a range of promising novel and experimental agents. The book also discusses counseling the high-risk patient. Several chapters incorporate models of care delivery, patient navigation for multidisciplinary care, genomic and risk assessment, and comparative effects of research in treatment decision-making. The book is designed as a management text for all health care professionals who provide care for prostate cancer patients as well as patients, families, and advocates. Extensive references offer opportunities for additional study.

Key Features:
•Delineates a practical, concise approach to multidisciplinary management of prostate cancer
•Provides a wide range of perspectives and expertise
•Written and edited by an international, multidisciplinary team of prostate cancer specialists
•Focuses on such key issues as special populations, screening controversies, patient counseling, and quality of life
•Includes discussion of important emerging topics such as gene profiling and targeted therapies and comparative effectiveness data

Contributors

Series Foreword

Preface

Acknowledgments

I.

Epidemiology, Screening, and Diagnosis

1 Introduction: The Multidisciplinary Approach to Prostate Cancer

Leonard G. Gomella

2.1 Epidemiology of Prostate Cancer

Kathryn M. Wilson

Lorelei A. Mucci

2.2 Diet and Prostate Cancer

James R. Marshall

2.3 Epidemiology: Obesity as a Risk Factor

Emma H. Allott

Stephen J. Freedland

3.1.1 Screening and Diagnosis: The Pros of PSA Screening

Janine L. Oliver

Gurdarshan S. Sandhu

Gerald L. Andriole

Robert L. Grubb III

3.1.2 The Argument Against Prostate Cancer Screening

Otis W. Brawley

3.1.3 How Do We Improve PSA Accuracy?

Toru Sugihara

Michael W. Kattan

3.2 Screening and Diagnosis: An Update on the ISUP-Modified Gleason Score and Its Controversies

Ibrahim Kulac

Angelo M. DeMarzo

3.3 Evaluation of Distant Disease: The Utility of Nuclear Imaging

Dima Raskolnikov

Baris Turkbey

Liza Lindenberg

Peter L. Choyke

Peter A. Pinto

4 Current Approaches to Prostate Cancer Staging and Risk Stratification: In the Midst of a Paradigm Shift

Chad A. Reichard

Eric A. Klein

5.1 Novel Molecular and Genotype Profiling in Prostate Cancer: The Future of Screening, Diagnosis, and Staging

Heesun Shin

Ismael A. Vergara

Anirban P. Mitra

Timothy J. Triche

Elai Davicioni

5.2 Genomics and Risk Assessment

Hao G. Nguyen

Matthew R. Cooperberg

Peter R. Carroll

5.3 Future Direction: Novel Urine and Serum Markers

Waleed A. Hassen

5.4 Morphometric and Systems Pathology: The Future of Screening, Diagnosis, and Staging

Michael J. Donovan

Faisal M. Khan
Richard Scott

Gerardo Fernandez

Carlos Cordon-Cardo

5.5.1 PET: The Future of Screening, Diagnosis, and Staging for Prostate Cancer

Mathew L. Thakur

Edouard J. Trabulsi

Sung M. Kim

Charles M. Intenzo

Leonard G. Gomella

5.5.2 DCE MRI and MR Spectroscopy: The Future of Screening, Diagnosis, and Staging

Victor Sai

Antonio C. Westphalen

5.5.3 Future Direction: Contrast Ultrasound 109

Sanjay Kasturi

Edouard J. Trabulsi

Ethan J. Halpern

6 Counseling Patients With Clinically Localized, High-Risk Prostate Cancer

Jonathan L. Silberstein

James A. Eastham

II.

Treatment for Low-Risk, Localized Disease

7 Active Surveillance for Prostate Cancer: An Overview

Laurence Klotz

8 Treatment of Low-Risk, Localized Prostate Cancer: A Holistic Approach With Diet

Jillian Scambia

Annie Darves-Bornoz

Aaron Katz

9.1 Traditional Radical Prostatectomy

Zachary L. Smith

Thomas J. Guzzo

9.2 Laparoscopic Radical Prostatectomy: Techniques and Complications

Fernando Pablo Secin

Karim Touijer

9.3 Robotic Radical Prostatectomy: The Thomas Jefferson University Experience

Costas D. Lallas

Edouard J. Trabulsi

9.4 Surgical Training, Digital Capture, Virtual Reality, and the Future of Radical Prostatectomy

Costas D. Lallas

10.1.1 External Beam Radiation Therapy: Conventional Fractionation

David E. Greene

Richard K. Valicenti

10.1.2 Hypofractionated Radiation Therapy for Localized Prostate Cancer

Nicholas G. Zaorsky

Robert B. Den

10.1.3 Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Nicholas G. Zaorsky

Robert B. Den

10.1.4 Treatment of Low-Risk, Localized Prostate Cancer: Use of Proton Therapy

Phillip J. Gray

Ayal A. Aizer

Jason A. Efstathiou

10.2 Treatment of Low-Risk, Localized Prostate Cancer: Brachytherapy

Peter Grimm

11.1 Treatment of Low-Risk, Localized Prostate Cancer: General Principles of Ablative and Focal Therapies

Joshua A. Cohn

Aytekin Oto

Scott E. Eggener

11.2 Hyperthermia for Prostate Cancer

Mark Hurwitz

11.3 Ablative Techniques: Vascular Targeted Photodynamic Therapy

Ashley G. Winter

Jonathan A. Coleman

11.4 Laser Ablative Techniques for Prostate Cancer

Ashley G. Winter

Jonathan A. Coleman

11.5 Irreversible Electroporation (IRE) Prostate Ablation

Ashley G. Winter

Jonathan A. Coleman

12.1 Quality of Life With Surgery

Alana M. Murphy

Patrick J. Shenot

12.2 Quality of Life With Androgen Deprivation Therapy

Alana M. Murphy

Patrick J. Shenot

12.3 Quality of Life With External Beam Radiation Therapy

Steve K. Williams

Sameer Chopra

Farhang Rabbani

12.4 Quality of Life With Brachytherapy for Low-Risk Localized Prostate Cancer

Steve K. Williams

Farhang Rabbani

13 Role for Comparative Effectiveness Research in Treatment Decision Making

Ryan T. Jones

Mark V. Mishra

Timothy N. Showalter

14 Defining Treatment Failure for Localized Prostate Cancer: PSA and Beyond

Nicholas G. Zaorsky

Robert B. Den

Jianqing Lin

15 Prognosis After Biochemical Failure and Surrogate Endpoints for Prostate Cancer-Specific Mortality

Peter Orio

Nathan Bittner

III.

Treatment for High-Risk, Localized, and Locally Advanced Disease

16 Treatment of High-Risk Prostate Cancer: The Role of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy

Thomas J. Pugh

IV.

Treatment of Disseminated Disease

17 Salvage Therapy for Rising PSA

Judd W. Moul

18 Metastatic Hormone Sensitive Prostate Cancer

Jean Hoffman-Censits

William Kevin Kelly

19.1 Metastatic Castrate-Resistant Prostate Cancer: Mechanisms of Hormone Escape

Susan F. Slovin

19.2 Metastatic Castrate-Resistant Prostate Cancer: Role of Chemotherapy and Multifaceted Treatment Paradigms

Abdel Hai Alqwasmi

Nicholas G. Zaorsky

Ulka Vaishampayan

19.3 Metastatic Castrate-Resistant Prostate Cancer: Role of Androgen Signaling Inhibitors

Austin Poole

Ajjai Alva

Julia Batten

Neeraj Agarwal

19.4.1 Radiation and the Immune System

Andrew Sharabi

Charles Drake

19.4.2 Immunotherapy: Agents Targeting Prostate Cancer

Gurveen Kaur

Naveed H. Akhtar

Beerinder K. Singh

Scott T. Tagawa

19.5 Treatment of Bony Metastases: Inhibitors of Bone Resorption

Clara Hwang

Elisabeth I. Heath

19.6 Treatment of Bone Metastases: Radiopharmaceuticals

Hossein Jadvar

Leslie Ballas

David I. Quinn

19.7 Prognostication of Metastatic Castration-Resistant Prostate Cancer

Alan D. Smith

Joaquin Mateo

Johann S. de Bono

Index